[A20-29] Ceftolozane/tazobactam (acute pyelonephritis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2020
Project no.:
A20-29
Commission:
Commission awarded on 17.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Adults with acute pyelonephritis
Result of dossier assessment:
Added benefit not proven due to lack of suitable study data
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-28 | Ceftolozane/tazobactam (complicated urinary tract infections) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-27 | Ceftolozane/tazobactam (complicated intra-abdominal infections) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-26 | Ceftolozane/tazobactam (hospital-acquired pneumonia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G22-18 | Ceftolozane/tazobactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V | Commission completed |
| G22-27 | Ceftolozane/tazobactam (bacterial infections < 18 years) - Assessment according to §35a (para. 1c) Social Code Book V | Commission completed |